2.33 USD
-0.05 (-2.1%)
At close: Feb 11, 2026
2.36 USD
+0.03 (+1.29%)
After Hours: 2/11/2026, 8:00:01 PM
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 191 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of HITI while its profitability can be described as average. HITI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- HITI had negative earnings in the past year.
- In the past year HITI had a positive cash flow from operations.
- HITI had negative earnings in each of the past 5 years.
- HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- HITI has a better Return On Assets (-14.54%) than 62.83% of its industry peers.
- HITI has a Return On Equity (-57.92%) which is in line with its industry peers.
- HITI has a Return On Invested Capital of 5.17%. This is amongst the best in the industry. HITI outperforms 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.54% | ||
| ROE | -57.92% | ||
| ROIC | 5.17% |
ROA(3y)-11.05%
ROA(5y)-14.75%
ROE(3y)-30.28%
ROE(5y)-32.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HITI has a better Operating Margin (2.74%) than 78.01% of its industry peers.
- In the last couple of years the Operating Margin of HITI has grown nicely.
- HITI's Gross Margin of 25.99% is in line compared to the rest of the industry. HITI outperforms 54.97% of its industry peers.
- In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.74% | ||
| PM (TTM) | N/A | ||
| GM | 25.99% |
OM growth 3YN/A
OM growth 5Y10.73%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.78%
GM growth 5Y-6.82%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HITI is destroying value.
- Compared to 1 year ago, HITI has more shares outstanding
- HITI has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for HITI is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.59, we must say that HITI is in the distress zone and has some risk of bankruptcy.
- HITI has a Altman-Z score of 1.59. This is comparable to the rest of the industry: HITI outperforms 58.64% of its industry peers.
- HITI has a debt to FCF ratio of 8.31. This is a slightly negative value and a sign of low solvency as HITI would need 8.31 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 8.31, HITI belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
- A Debt/Equity ratio of 0.94 indicates that HITI is somewhat dependend on debt financing.
- HITI has a Debt to Equity ratio of 0.94. This is in the lower half of the industry: HITI underperforms 72.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 8.31 | ||
| Altman-Z | 1.59 |
ROIC/WACC0.56
WACC9.2%
2.3 Liquidity
- A Current Ratio of 1.37 indicates that HITI should not have too much problems paying its short term obligations.
- HITI's Current ratio of 1.37 is on the low side compared to the rest of the industry. HITI is outperformed by 73.30% of its industry peers.
- A Quick Ratio of 0.70 indicates that HITI may have some problems paying its short term obligations.
- The Quick ratio of HITI (0.70) is worse than 85.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
- The earnings per share for HITI have decreased strongly by -884.13% in the last year.
- HITI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.72%.
- HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.14% yearly.
EPS 1Y (TTM)-884.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)13.72%
Revenue growth 3Y18.51%
Revenue growth 5Y48.14%
Sales Q2Q%18.61%
3.2 Future
- The Earnings Per Share is expected to grow by 30.45% on average over the next years. This is a very strong growth
- HITI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.96% yearly.
EPS Next Y121.5%
EPS Next 2Y60.32%
EPS Next 3Y46.8%
EPS Next 5Y30.45%
Revenue Next Year29.67%
Revenue Next 2Y19.93%
Revenue Next 3Y18.21%
Revenue Next 5Y13.96%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 23.70, the valuation of HITI can be described as rather expensive.
- 74.87% of the companies in the same industry are more expensive than HITI, based on the Price/Forward Earnings ratio.
- HITI is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.7 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HITI is valued cheaper than 90.58% of the companies in the same industry.
- HITI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HITI is cheaper than 85.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.86 | ||
| EV/EBITDA | 8.31 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- HITI's earnings are expected to grow with 46.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.32%
EPS Next 3Y46.8%
5. Dividend
5.1 Amount
- No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.33
-0.05 (-2.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29 2026-01-29/amc
Earnings (Next)03-16 2026-03-16
Inst Owners13.66%
Inst Owner Change0.16%
Ins Owners8.85%
Ins Owner ChangeN/A
Market Cap203.29M
Revenue(TTM)593.99M
Net Income(TTM)-50.75M
Analysts80
Price Target5.34 (129.18%)
Short Float %0.35%
Short Ratio0.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.04%
Min Revenue beat(2)0.98%
Max Revenue beat(2)1.09%
Revenue beat(4)3
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.13%
Revenue beat(12)9
Avg Revenue beat(12)0.97%
Revenue beat(16)13
Avg Revenue beat(16)7.41%
PT rev (1m)0.11%
PT rev (3m)0.78%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.49%
EPS NY rev (3m)-1.49%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.7 | ||
| P/S | 0.46 | ||
| P/FCF | 20.86 | ||
| P/OCF | 11.55 | ||
| P/B | 3.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.31 |
EPS(TTM)-0.46
EYN/A
EPS(NY)0.1
Fwd EY4.22%
FCF(TTM)0.11
FCFY4.79%
OCF(TTM)0.2
OCFY8.66%
SpS5.02
BVpS0.74
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.54% | ||
| ROE | -57.92% | ||
| ROCE | 6.54% | ||
| ROIC | 5.17% | ||
| ROICexc | 6.4% | ||
| ROICexgc | 17.98% | ||
| OM | 2.74% | ||
| PM (TTM) | N/A | ||
| GM | 25.99% | ||
| FCFM | 2.23% |
ROA(3y)-11.05%
ROA(5y)-14.75%
ROE(3y)-30.28%
ROE(5y)-32.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y8.85%
ROICexc growth 3YN/A
ROICexc growth 5Y9.97%
OM growth 3YN/A
OM growth 5Y10.73%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.78%
GM growth 5Y-6.82%
F-Score2
Asset Turnover1.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 8.31 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 43.8% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 2.21 | ||
| Cash Conversion | 58.77% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 1.59 |
F-Score2
WACC9.2%
ROIC/WACC0.56
Cap/Depr(3y)33.59%
Cap/Depr(5y)35.25%
Cap/Sales(3y)1.64%
Cap/Sales(5y)2.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-884.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y121.5%
EPS Next 2Y60.32%
EPS Next 3Y46.8%
EPS Next 5Y30.45%
Revenue 1Y (TTM)13.72%
Revenue growth 3Y18.51%
Revenue growth 5Y48.14%
Sales Q2Q%18.61%
Revenue Next Year29.67%
Revenue Next 2Y19.93%
Revenue Next 3Y18.21%
Revenue Next 5Y13.96%
EBIT growth 1Y6.44%
EBIT growth 3YN/A
EBIT growth 5Y64.03%
EBIT Next Year707.98%
EBIT Next 3Y142.78%
EBIT Next 5Y80.76%
FCF growth 1Y-48.76%
FCF growth 3YN/A
FCF growth 5Y16.8%
OCF growth 1Y-32.86%
OCF growth 3Y74.46%
OCF growth 5Y21.95%
HIGH TIDE INC / HITI FAQ
What is the fundamental rating for HITI stock?
ChartMill assigns a fundamental rating of 4 / 10 to HITI.
What is the valuation status for HITI stock?
ChartMill assigns a valuation rating of 5 / 10 to HIGH TIDE INC (HITI). This can be considered as Fairly Valued.
Can you provide the profitability details for HIGH TIDE INC?
HIGH TIDE INC (HITI) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for HITI stock?
The Earnings per Share (EPS) of HIGH TIDE INC (HITI) is expected to grow by 121.5% in the next year.